Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > News > Machine learning mortality predictions boost end-of-life conversations
  • News

Machine learning mortality predictions boost end-of-life conversations

  • 18 November 2020
  • Janet Fricker
Machine learning mortality predictions boost end-of-life conversations
Total
0
Shares
0
0
0
0
0

A study of the use of machine learning to predict the risk of dying within six months, combined with behavioural nudges, led to increased serious illness conversations between oncologists and cancer patients. “To our knowledge, this is one of the first randomized clinical trials testing the effect of real-time machine learning predictions and behavioural nudges on clinical care,” write the authors of the article (Manz CR et al. JAMA Oncol 2020).

Serious illness conversations are structured conversations between clinicians, patients, and families around prognosis, treatment goals, and end-of-life preferences (Fricker J. CancerWorld, 2020). While early discussions have been associated with less-aggressive care for cancer patients near the end of life, including increased hospice utilisation, and reduced chemotherapy and hospitalisation rates, most patients with cancer die without documented discussions about their goals and treatment preferences.

The study by Christopher Manz, from Dana-Farber Cancer Institute (Boston) and colleagues, set out to determine effects of integrating machine-learning mortality predictions with behavioural nudges on motivating serious illness conversations between clinicians and patients.

Overall, 78 oncology physicians from nine medical oncology clinics in the University of Pennsylvania Health System (who had all received training in serious illness conversations) were randomly assigned to control or intervention groups between June 17 and November 1 2019. The intervention consisted of three main components:

  • Component 1: Oncology clinicians received weekly emails with performance feedback on their serious illness conversations (indicating the number they had performed in the prior 4 weeks) and peer comparisons.
  • Component 2: With the email, oncology clinicians received a link to a secure dashboard where they could review up to six high-risk patients scheduled for the following week estimated to have high risk of mortality (≥10% predicted risk of 180-day mortality). Estimations used a validated machine learning algorithm that had been demonstrated to accurately predict 180-day mortality risk (Parikh RB et al. JAMA Netw. Open 2019).
  • Component 3: Oncology clinicians received a text message (which they could opt out of) on the morning of appointments with high-risk patients, reminding them to consider having a serious illness conversation.

The clinics included eight subspeciality clinics (breast, central nervous system, gastrointestinal, genitourinary, lymphoma, melanoma, myeloma, and thoracic or head and neck) and one general oncology clinic. The study involved 14,607 patients who had 26,059 physician encounters. It used a ‘stepped wedge cluster’ randomised trial design, involving random and sequential crossover of clusters from control to intervention groups, until all clusters were exposed. Mortality predictions were updated weekly, with the result that patients assigned to the ‘high-risk’ group could change between encounters.

Results for all encounters showed that serious illness conversations were conducted for 1.3% of patients in the control group versus 4.6% in the intervention group (adjusted difference in percentage points 3.3; 95%CI 2.3−4.5; P<0.001). Among the 4,124 high-risk patient encounters, serious illness conversationss were conducted for 3.6% of patients in the control group versus 15.2% in the intervention group (adjusted difference in percentage points 11; 95%CI 8.2−12.15; P<0.001).

“Behavioral nudges combined with machine learning mortality predictions can positively influence clinician behavior and may be applied more broadly to improve care near the end of life,” conclude the authors, adding that longer-term studies are needed to assess whether algorithm-based interventions result in improved clinical outcomes for patients.

A key innovation of the study, they write, was integrating principles of behavioural economics into the machine-learning-based intervention, including peer comparisons, performance feedback, and opt-out reminders, which have been used successfully in other clinical settings to change clinician behaviour.

Although the intervention effect was strongest for high-risk patients flagged by the algorithm, the study still detected an increase in serious illness conversations among patients not deemed to be at high risk of dying within six months. “This off-target effect may have occurred because the clinicians who received the intervention became accustomed to actively considering mortality risk in their clinical practice, resulting in an increase in SICs [serious illness conversations] for patients who may have a poor prognosis but were not flagged by the algorithm as high risk,” write the authors.

Commenting on the study to Cancer World, Stephanie Harman, from Stanford Health Care, in Stanford, California, says, “What’s novel about this study is introducing behavioural nudges into the routine workflow to increase the number of SICs. Nudges have previously been shown to be effective in health care quality improvements.”

Strengths of the study, she adds, include input from primary frontline oncologists, and the general oncology population (not just high risk patients), underscoring the effectiveness of large-scale implementation. “But the algorithm may not be replicable in other health-care systems if they do not have the same level of biomedical informatics support, expertise, or cannot afford the approach,” she says.

Illustration: Maddalena Carrai

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Interviews to the Expert

The cost of cancer in Europe

  • 16 November 2020
  • Alberto Costa
View Post
Next Article
  • Articles

Rapid palliation of bone mets: it’s effective and easy, so why aren’t we all doing it?

  • 20 November 2020
  • Marc Beishon
View Post
You May Also Like
View Post
  • News

Six Months of CancerWorld Under p53: A Report of Renewal, Responsibility, and Reach

  • Yeva Margaryan
  • 19 August 2025
View Post
  • News

CancerWorld #106 (August 2025)

  • Yeva Margaryan
  • 15 August 2025
View Post
  • Articles
  • Medicine
  • News

Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy

  • Sophie Fessl
  • 12 August 2025
View Post
  • News

BRCA1/BRCA2 Mutations Carriers at Greater Risk for Anaplastic Large Cell Lymphoma Associated with Breast Implants

  • Janet Fricker
  • 12 August 2025
View Post
  • News

How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI

  • Janet Fricker
  • 12 August 2025
View Post
  • Delivery of Care
  • News
  • Senza categoria

A Bold Step into Building Africa’s Cancer Atlas

  • Esther Nakkazi
  • 22 July 2025
View Post
  • News

Cannabis Use is Linked to Increased Mortality in Colon Cancer Patients

  • Janet Fricker
  • 22 July 2025
View Post
  • News

How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma

  • Janet Fricker
  • 4 July 2025
search
CancerWorld #105 Download CancerWorld #105 Download CancerWorld #104 Download CancerWorld #103 Download CancerWorld #102 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Six Months of CancerWorld Under p53: A Report of Renewal, Responsibility, and Reach
    • 19 August 2025
  • CancerWorld #106 (August 2025)
    • 15 August 2025
  • Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy
    • 12 August 2025
  • BRCA1/BRCA2 Mutations Carriers at Greater Risk for Anaplastic Large Cell Lymphoma Associated with Breast Implants
    • 12 August 2025
  • How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI
    • 12 August 2025
Article
  • When Hope is Hard to Find, Folk Remedies Step In
    • 25 August 2025
  • Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy
    • 12 August 2025
  • Michel Goldman: A Teacher Until the End
    • 12 August 2025
Social

Would you follow us ?

Contents
  • Michel Goldman: A Teacher Until the End
    • 12 August 2025
  • Jennifer Buell: Turning Living Cells into Living Medicines
    • 12 August 2025
  • “Moving Mountains with Passion”: The Life and Legacy of Baroness Françoise Meunier
    • 22 July 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.